

Kevin K Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10156639/publications.pdf>

Version: 2024-02-01

78
papers

15,468
citations

53660

45
h-index

71532

76
g-index

79
all docs

79
docs citations

79
times ranked

9654
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2014, 370, 2071-2082.	13.9	3,351
2	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e44-e68.	2.5	2,678
3	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>New England Journal of Medicine</i> , 2019, 381, 1718-1727.	13.9	1,338
4	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2015, 46, 976-987.	3.1	803
5	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. <i>Lancet Respiratory Medicine</i> , 2018, 6, 138-153.	5.2	739
6	Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 538-542.	2.5	664
7	Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1025-1032.	2.5	562
8	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSISA® trials. <i>Respiratory Medicine</i> , 2016, 113, 74-79.	1.3	335
9	Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 453-460.	5.2	331
10	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <i>Lancet Respiratory Medicine</i> , 2020, 8, 726-737.	5.2	279
11	Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. <i>European Respiratory Journal</i> , 2016, 47, 588-596.	3.1	277
12	What's in a name? That which we call IPF, by any other name would act the same. <i>European Respiratory Journal</i> , 2018, 51, 1800692.	3.1	226
13	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 22-32.	5.2	200
14	Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2009, 135, 1557-1563.	0.4	189
15	Roger S. Mitchell Lecture. Rheumatoid Lung Disease. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 443-448.	3.5	168
16	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. <i>European Respiratory Journal</i> , 2015, 46, 512-520.	3.1	164
17	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000212.	1.2	151
18	The natural history of progressive fibrosing interstitial lung diseases. <i>European Respiratory Journal</i> , 2020, 55, 2000085.	3.1	148

#	ARTICLE	IF	CITATIONS
19	CT Scan Findings of Probable Usual Interstitial Pneumonitis Have a High Predictive Value for Histologic Usual Interstitial Pneumonitis. <i>Chest</i> , 2015, 147, 450-459.	0.4	144
20	Update in the Diagnosis and Management of Pulmonary Vasculitis. <i>Chest</i> , 2006, 129, 452-465.	0.4	138
21	Clinically Significant Interstitial Lung Disease in Limited Scleroderma. <i>Chest</i> , 2008, 134, 601-605.	0.4	136
22	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. <i>European Respiratory Journal</i> , 2015, 46, 1370-1377.	3.1	129
23	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. <i>Respiratory Medicine</i> , 2016, 119, 150-154.	1.3	111
24	Pulmonary Vasculitis. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 48-57.	3.5	106
25	Respiratory Bronchiolitis-Interstitial Lung Disease. <i>Chest</i> , 2007, 131, 664-671.	0.4	104
26	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. <i>Chest</i> , 2021, 160, e97-e156.	0.4	104
27	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 12-21.	2.5	102
28	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. <i>European Respiratory Journal</i> , 2015, 46, 1740-1750.	3.1	97
29	Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2009, 136, 841-848.	0.4	90
30	Acute exacerbations of fibrotic interstitial lung diseases. <i>Respirology</i> , 2020, 25, 525-534.	1.3	85
31	Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis. <i>Chest</i> , 2008, 134, 844-850.	0.4	84
32	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). <i>BMJ Open Respiratory Research</i> , 2019, 6, e000422.	1.2	79
33	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. <i>Chest</i> , 2020, 158, 646-659.	0.4	79
34	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1646-1654.	1.5	77
35	Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2016, 149, 491-498.	0.4	75
36	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. <i>JCI Insight</i> , 2016, 1, .	2.3	73

#	ARTICLE	IF	CITATIONS
37	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 388-396.	5.2	69
38	Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1151-1160.	2.5	68
39	The NHLBI LAM Registry. <i>Chest</i> , 2019, 155, 288-296.	0.4	67
40	Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients. <i>Chest</i> , 2016, 149, 201-208.	0.4	58
41	The Usefulness of Chest CT Imaging in Patients With Suspected or Diagnosed COVID-19. <i>Chest</i> , 2021, 160, 652-670.	0.4	56
42	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , 2017, 26, 170050.	3.0	54
43	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.4	53
44	Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2016, 31, 939-946.	0.5	51
45	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. <i>European Respiratory Journal</i> , 2015, 46, 243-249.	3.1	48
46	Minor Salivary Gland Biopsy To Detect Primary Sjögren Syndrome in Patients With Interstitial Lung Disease. <i>Chest</i> , 2009, 136, 1072-1078.	0.4	47
47	Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis and Outcomes. <i>American Journal of the Medical Sciences</i> , 2019, 357, 359-369.	0.4	45
48	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. <i>Thorax</i> , 2019, 74, 1131-1139.	2.7	43
49	Seasonal Variation. <i>Chest</i> , 2009, 136, 16-22.	0.4	37
50	Smoking-related idiopathic interstitial pneumonia. <i>European Respiratory Journal</i> , 2014, 44, 594-602.	3.1	36
51	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2014, 146, 1256-1262.	0.4	28
52	Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?. <i>European Respiratory Journal</i> , 2020, 55, 1802465.	3.1	25
53	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	2.5	21
54	Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. <i>European Respiratory Journal</i> , 2022, 59, 2004587.	3.1	19

#	ARTICLE	IF	CITATIONS
55	Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. <i>Clinics in Chest Medicine</i> , 2004, 25, 759-772.	0.8	18
56	Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. <i>Respirology</i> , 2022, 27, 333-340.	1.3	18
57	Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. <i>Patient Related Outcome Measures</i> , 2016, 7, 29.	0.7	17
58	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. <i>Respirology</i> , 2022, 27, 294-300.	1.3	15
59	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. <i>ERJ Open Research</i> , 2021, 7, 00805-2020.	1.1	14
60	Algorithmic Approach to the Diagnosis of Organizing Pneumonia. <i>Chest</i> , 2022, 162, 156-178.	0.4	13
61	Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of <i>MUC5B</i> and <i>DSP</i> in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1259-1270.	2.5	12
62	Fibrotic hypersensitivity pneumonitis. <i>Current Respiratory Care Reports</i> , 2014, 3, 170-178.	0.6	11
63	Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 214-228.	0.8	11
64	COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. <i>Chest</i> , 2016, 150, 276-278.	0.4	9
65	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 168-178.	1.0	9
66	Advances in the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 537-552.	1.0	8
67	Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 37.	0.6	7
68	The progressive fibrotic phenotype in current clinical practice. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 368-373.	1.2	7
69	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 97.	1.4	7
70	Definitions of disease: Should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?. <i>Respiratory Investigation</i> , 2015, 53, 88-92.	0.9	5
71	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , 2019, 36, 3059-3070.	1.3	4
72	Lung Hyperlucency. <i>Chest</i> , 2020, 157, 119-141.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	3
74	Fibrose pulmonar idiopática: uma década de progressos. <i>Jornal Brasileiro De Pneumologia</i> , 2006, 32, 249-260.	0.4	2
75	The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. <i>American Journal of the Medical Sciences</i> , 2019, 357, 405-410.	0.4	1
76	Response. <i>Chest</i> , 2007, 131, 940-941.	0.4	0
77	Preface. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, xi-xii.	0.7	0
78	Reply to comment on "The natural history of progressive fibrosing interstitial lung diseases". <i>European Respiratory Journal</i> , 2020, 56, .	3.1	0